Toll like receptor 4 (TLR4) is crucial in induction of innate immune response through recognition of invading pathogens or endogenous alarming molecules.
Introduction
Sepsis is a multifaceted host systemic inflammatory response syndrome (SIRS) caused by infection, and could be significantly amplified by endogenous factors [1] . Sepsis and subsequent organ dysfunction is one of the leading causes of death in intensive care units (ICUs) [2] . The lipopolysaccharide (LPS) from Gram-negative bacteria is a well-established early driver of sepsis. LPS could be detected by both cell surface and intracellular receptors, known as Toll like receptor 4 (TLR4) and caspase-4/5/11, respectively [3] [4] [5] . Caspases-and TLR4-dependent release of danger-associated molecular patterns (DAMPs) into the extracellular space during LPS-induced sepsis contributes to uncontrolled inflammation and host mortality [3, 6] .
High-mobility group box 1 (HMGB1), a ubiquitous nuclear and cytosolic protein, is a strong DAMP mediator of excessive inflammation in sepsis [7, 8] .
Extracellular HMGB1, released in late phase of sepsis, also signals through TLR4 in macrophages to induce cytokine release [9] . Thus, inhibitors of HMGB1-TLR4 signaling may provide a broad therapeutic time window for sepsis. In previous study, our group identified HIV protease inhibitor (PI) saquinavir (SQV) could block HMGB1 driven TLR4-MyD88 activation in macrophages and be protective in murine sepsis model [10] . SQV, as the first FDA-approved HIV protease inhibitor (PI), has been used for prolonged periods without severe side effects in HIV seropositive subjects since 1995.
Unexpectedly, SQV and other HIV PIs possess pleiotropic antitumor and immunomodulatory effects, via suppressing activity of several mammalian targets in a concentration-dependent manner, including matrix metalloproteinase 2, 20S, 26S proteasome and akt phosphorylation [11] . However, it remains unknown whether SQV is a HMGB1-specific and MyD88-dependent TLR4 signaling inhibitor and which precise signaling element of TLR4 is targeted by SQV. Therefore, the present study investigated the molecular mechanism of SQV exerting anti-inflammatory property and modulating TLR4 activation.
Results

LPS-induced TLR4-MyD88 activation was inhibited by Saquinavir.
Both LPS and disulfide HMGB1 signal through TLR4/MD2/CD14 complex at cell membrane level [12, 13] . In previous study, we reported SQV (Fig.1A) blocks HMGB1-induced TNF-α production in human and mouse macrophages [10] . Here we tested whether SQV is a HMGB1-specific TLR4 inhibitor by evaluating the impact of SQV on LPS triggered TLR4 activation in cultured THP-1 monocyte-derived macrophages. SQV was found to potently suppress TNF-α release in THP-1 macrophages in response to LPS (Fig. 1B) , while the compound control, another first-line HIV PI Atazanaivr didn't affect LPS induced TNF-α production. Besides, in HEK293 cell transfected with TLR4/CD14/MD2 and NF-κB SEAP reporting system, NF-κB activation was significantly down-regulated by SQV (Fig. 1C) . As shown before, HMGB1-TLR4 activated MyD88 pathway (IRAK4 phosphorylation and IRAK1 degradation) could also be prevented by SQV [10] . To determine whether SQV diminishes TLR4-MyD88 activation in a ligand-independent manner, we assessed degradation of IRAK1 in human macrophages exposed to LPS in the presence or absence of SQV. LPS stimulation led to the loss of IRAK1, but SQV attenuated LPS induced IRAK1 degradation and consequent IKK α/β phosphorylation (Fig. 1D) . These results support the conclusion that SQV suppresses both LPS and HMGB1 induced TLR4-MyD88 activation.
LPS-activated TLR4-TRIF pathway was blocked by SQV.
Except MyD88, TLR4 signal pathway relies on the other critical adaptor protein TRIF, which is recruited by TLR4 after LPS induced TLR4 endocytosis into endosome [12, 14] . The TRIF-dependent pathway culminates in the activation of both IRF3 and NF-κB. IRF3 is phosphorylated and transferred to nucleus promoting interferon-β transcription [14] . LPS led to the phosphorylation of IRF3 when stimulating THP-1 macrophages for 60 mins ( Fig. 2A) , and this phosphorylation was unexpectedly diminished by SQV, without affecting total IRF3. More interestingly, in the presence of SQV, LPS induced TLR4 endocytosis was decreased, as well as THP-1 macrophage polarization (Fig. 2B) . Together, these findings indicate that SQV exerts anti-inflammatory effect through both TLR4-MyD88 and TLR4-TRIF pathways.
SQV does not suppress the activation of MyD88 and TRIF induced by TLR 1/2 and 3
agonists.
We couldn't exclude the possibility that the targets of SQV lie in MyD88 or TRIF pathway. We were also curious about the selectivity of SQV on different Toll like receptors signaling. Therefore, we evaluated the impact of SQV on MyD88 and TRIF pathway when stimulated by other receptor-agonists engagement, using PMA-derived THP-1 macrophages. Since TLR1/2 is a MyD88-dependent cell surface TLR heterodimer [14] , its specific agonist Pam3CSK4 induced phosphorylation of IRAK4 and degradation of IRAK1 ( Fig. 3A and 3B ), however these signal events were not affected even in the presence of SQV. TLR3 is the only TRIF-dependent and MyD88-independent TLR [14] . Poly (I:C), as the TLR3 agonist, triggered phosphorylation of IRF3, which was unaltered by SQV (Fig. 3C ). Together, these results demonstrate that SQV specifically targets TLR4 receptor complex, rather than signal elements within MyD88 or TRIF pathways.
SQV suppresses LPS and HMGB1 induced TLR4 dimerization.
The dimerization of TLR4 was shown to be a prerequisite for the ligand-induced TLR4 activation and acts upstream of MyD88 and TRIF pathway [15] . Since SQV inhibits both MyD88 and TRIF activation induced by LPS, therefore we next determined whether SQV disrupts LPS-induced dimerization of TLR4. For these studies, we used HEK293 cells stably transfected with MD2, CD14 and HA tagged human TLR4 as described previously [10] . We evaluated the dimerization of TLR4 by co-immunoprecipitation of TLR4-HA and transiently transfected TLR4-Myc. The dimerization, which was enhanced at 30 mins by LPS stimulation, was suppressed by SQV, while SQV didn't modify the expression level of TLR4-Myc or the baseline level of TLR4 dimerization (Fig. 4A ). Similar result was observed when using a different tagged TLR4 as TLR4-GFP in the case of HMGB1 stimulation (Fig. 4B) . To explore the possible binding site of SQV on TLR4, an in silico molecular docking experiment was performed. The potential binding site was displayed in Fig 4C, showing the hydrophobic P3 and P1' groups of SQV were embedded into the grooves of TLR4, overlapping the highlighted residues (Red) involved in the core dimerization interface of TLR4 [6] . Therefore, the anti-inflammatory effect of SQV may initially be due to its ability to block TLR4 dimerization.
Discussion
An increasing body of evidence highlights direct immunomodulatory effects of SQV in both experimental and clinical scenarios. Other than sepsis model, the preclinical data reported that SQV was protective in murine models of vascular intimal hyperplasia [16] , liver ischemia-reperfusion (IR) injury [10] , and lung Injury induced by liver warm IR [17] or mechanical ventilation [18] . In clinical aspect, a 6-month course of SQV was shown to reduce proteinuria and had a steroid-sparing effect in patients with nephrotic syndrome [19] . Recently, our colleagues proposed an exploratory clinical study to determine the safety and potential clinical benefit of the combination of HIV-PIs SQV and ritonavir in patients with idiopathic pulmonary arterial hypertension (IPAH) [20] . The basic mechanism of action is that SQV interact with human protein forming a drug-target complex, exerting off-label effects observed above. The mammalian target spectrum of SQV varies in a concentration-dependent manner. Additionally, based on current identified human targets of SQV, the novel targets may not definitely share similar structural properties as HIV proteases [11] .
In this study, we provide the evidence that the anti-inflammatory mechanism of SQV arises from its direct modulation on TLR4-mediated signaling at the receptor level. TLR4 initiates immune response in the setting of infection and sterile inflammation through recognition of DAMPs and pathogen-associated molecular patterns (PAMPs). In sepsis scenario, LPS binding induces the formation of a symmetric M-shaped TLR4-MD-2-LPS multimer composed of two copies of the complex. Dimerization of TLR4 leads to the recruitment of MAL and MYD88 and the activation of the serine/threonine kinase IRAK4, which engages with the NF-κB and mitogen-activated protein kinase cascades, leading to the induction of pro-inflammatory cytokines [6] . TLR4 can also recruit TRIF (TIR domain-containing adaptor-inducing interferon-β) and TRAM (TRIF-related adaptor molecule) after endocytosis into endosomes, which leads to the activation of the transcription factor IRF3 and the induction of genes such as those encoding Type I interferons (IFNs) [14] .
Therefore, suppression of TLR4 dimerization delete this scaffold for MyD88 or TRIF recruitment, thus preventing further signaling [21, 22] . Several studies have suggested that TLR4 dimerization could be a beneficial therapeutical target for anti-inflammation agents.
Our previous study happened to find, in human macrophages, SQV blocks HMGB1 activated TLR4-MyD88 pathway through inhibiting a cysteine protease cathepsin V other than proteasome. To current knowledge, TLR4 is the only toll like receptor signaling through both MyD88 and TRIF downstream pathway. LPS is the mostly investigated TLR4 ligand and a critical sepsis inducer. To evaluate therapeutical potential of SQV in sepsis, we tested the effect of SQV on LPS-triggered TLR4 signal pathway at both receptor and nuclear factor level. SQV, rather than control drug ATV, was found to inhibit LPS induced IRAK1 degradation and IKK α/β phosphorylation (Fig. 1C) , as well as TNF-α (Fig. 1B) production and NF-kB (Fig. 1D) activation in human macrophages and HEK293 cell system. These findings confirmed that the target of SQV in TLR4 signaling lies upstream of IKK α/β and proteasome.
Further probing on LPS-induced TRIF pathway showed that SQV blocks TLR4 endocytosis into endosome (Fig. 2B ) and consequent IRF3 phosphorylation in response to LPS (Fig. 2A) . These results suggest that SQV is a ligand-independent TLR4 inhibitor and could suppress both MyD88-and TRIF-dependent pathways in LPS-activated TLR4 signaling.
It is possible that SQV could target some components in MyD88 and TRIF pathways, respectively. Pam3CSK4 engages with TLR1 and TLR2 heterodimer, then the ligand-receptor recruit MyD88 from cell membrane and initates IRAK4 phosphorylation and IRAK1 degradation. Poly (I:C) is recognized by TLR3 homodimer at the endolysosome, followed by recruitment of TRIF and IRF3 phosphorylation.
Pam3CSK4-TLR1/2-MyD88 and Poly (I:C)-TLR3-TRIF pathways share similar signaling components with LPS-TLR4-MyD88/TRIF pathways. However, both IRAK4 phosphorylation and IRKA1 degradation induced by Pam3CSK4 was not attenuated in the presence of SQV (Fig. 3A and B) . Neither is Poly (I:C) triggered IRF3 phosphorylation (Fig. 3C) . Together, these results indicate that the molecular targets for SQV include TLR4 receptor complex rather than downstream components in MyD88 or TRIF pathways.
Our immunoprecipitation results demonstrated that SQV could block both LPS and HMGB1 induced TLR4 dimerization ( Fig. 4A and B) , consistent with the hypothesis above. Futhurmore, docking analysis implies SQV may interact directly with F440 residue of TLR4, which is located on the TLR4 dimerization interface. The results of these experiments contribute to a novel mechanism for SQV modulating inflammatory response to TLR4 activation.
Materials and methods
Cell culture
Human monocytic THP-1 (ATCC) cells were differentiated for 12 h with 200 ng/mL PMA. HEK293 (ATCC), HEK293 stably transfected with CD14/MD2 and TLR4-HA or TLR4-Myc/GFP and human TLR4/NF-kB/SEAP reporter HEK293 cells (Invivogen) were grown at 37°C and 5% CO2, in DMEM (10% FBS, 2 mmol/L L-GLN, 100 U/mL PS, 1 mmol/L NaP, 100 μg/mL Normocin) (InvivoGen). 
Immunoprecipitation and immunoblot
Cells were lysed in 1% NP-40, 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 10% glycerol and protease inhibitors (Sigma-Aldrich, Roche). After clearing by centrifugation, total protein content was quantified using a BCA kit and 1000 μg were immunoprecipitated (IP) overnight using anti-mouse/rabbit beads (Rockland) and corresponding antibodies. IP and input fractions were subjected to SDS-PAGE and Western blot analysis.
NF-kappaB SEAP reporter assay
Human TLR4/NF-kB/SEAP reporter HEK293 cells stably transfected with MD2/CD14 plasmid were treated in HEK-Blue detection medium (Invivogen). SEAP levels in the medium were detected as the OD at 630 nm by spectrophotometer.
Immunocytochemistry and immunoassay
PMA-differentiated THP-1 cells, seeded on coverlips, were fixed with 4% paraformaldehyde and then were made permeable by incubation in PBS containing 0.5% Triton X-100. After being blocked with 2% BSA, monolayer cells were stained for Cathepsin V (R&D MAB1080; green) and EEA-1 (Novus NBP1-05962; red).
Fluorescence images were visualized with AxioVision 3.1 software (Carl Zeiss). Cell supernatants were assayed by enzyme-linked immunosorbent assay (ELISA) for TNF-α (R&D Systems).
In silico molecular docking experiment
The TLR4-SQV docking studies were carried out based on the crystallography structures of human TLR4 structure (PDB: 3FXI). To prepare the receptor molecule for docking, all solvent molecules and the ligands in the structure were removed. The hydrogen atoms were added to the receptor structure. The grid maps was calculated by by AutoGrid v4.2 including the whole structure of a TLR4 monomer. The docking procedure was performed using AutoDock v4.2. The docking searches were not constrained in certain regions. The docked conformations of SQV were ranked by the lowest binding energy. Human TLR4 dimer interface was identified using PDBe PISA v1.52.
Statistical Analysis
Data are expressed as means±SEM from at least three independent experiments.
One-way analysis of variance (ANOVA) with Tukey post hoc test was used for comparison among all different groups. A P value of < 0.05 was considered statistically significant: # P < 0.01, unless otherwise indicated. The panels are representative data from more than three independent experiments. 
Figures and legends
